Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

4.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

6.2K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

5.3K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.3K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

7.0K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Efficacy and safety of triptorelin acetate microspheres for injection versus triptorelin acetate for injection in Chinese patients with endometriosis: a multicenter, randomized, double-blind, phase Ⅲ non-inferiority clinical trial].

Zhonghua fu chan ke za zhi·2026
Same author

The predictive value of <sup>18</sup>F-FDG PET/CT metabolic parameters and radiomics characteristics for microvascular invasion of hepatocellular carcinoma.

Radiography (London, England : 1995)·2025
Same author

[Efficacy and safety of stereoelectroencephalography-guided 3D radiofrequency thermocoagulation for the treatment of drug-resistant medial temporal lobe epilepsy with hippocampal sclerosis].

Zhonghua yi xue za zhi·2025
Same author

[Molluscicidal effect and costs of spraying pyriclobenzuron with drones against <i>Pomacea canaliculata</i>].

Zhongguo xue xi chong bing fang zhi za zhi = Chinese journal of schistosomiasis control·2024
Same author

Dispersion kinks from electronic correlations in an unconventional iron-based superconductor.

Nature communications·2024
Same author

[Distribution and seasonal fluctuation of visceral leishmaniasis vectors sandflies in Henan Province in 2023].

Zhongguo xue xi chong bing fang zhi za zhi = Chinese journal of schistosomiasis control·2024

Related Experiment Video

Updated: Apr 27, 2026

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity
07:09

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

7.1K

CSNK1α1 mediates malignant plasma cell survival.

Y Hu1, W Song1, D Cirstea1

  • 1LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Leukemia
|June 26, 2014
PubMed
Summary

Targeting casein kinase 1-alpha1 (CSNK1α1) shows promise as a novel multiple myeloma (MM) therapy. Inhibiting CSNK1α1 induces MM cell death and may prevent disease progression, offering new treatment avenues.

More Related Videos

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

9.3K
In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
10:26

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

12.3K

Related Experiment Videos

Last Updated: Apr 27, 2026

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity
07:09

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

7.1K
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

9.3K
In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
10:26

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

12.3K

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Multiple myeloma (MM) is a hematologic malignancy with limited therapeutic options.
  • Proteasome inhibitors are a standard MM treatment, but resistance can develop.
  • Novel therapeutic targets are needed to overcome resistance and improve patient outcomes.

Purpose of the Study:

  • To investigate the role of casein kinase 1-alpha1 (CSNK1α1) in multiple myeloma (MM).
  • To evaluate CSNK1α1 inhibition as a potential therapeutic strategy for MM, including bortezomib-resistant cases.
  • To explore the involvement of CSNK1α1 in MM initiation and progression.

Main Methods:

  • CSNK1α1 expression analysis in MM cell lines and patient samples.
  • Inhibition of CSNK1α1 using D4476 and small hairpin RNAs (shRNAs).
  • Cell cycle analysis, apoptosis assays, and cytotoxicity studies in MM cells.
  • In vivo studies using mouse models of MM and oncogene-induced tumors.

Main Results:

  • CSNK1α1 is expressed in MM cells and its inhibition induces G0/G1 arrest, G2/M arrest, and apoptosis.
  • CSNK1α1 inhibition demonstrates cytotoxicity in bortezomib-resistant MM cells and enhances bortezomib efficacy.
  • CSNK1α1 signaling pathways involve CDKN1B, P53, and FADD, with affected gene signatures including interferon-α and tumor necrosis factor-α.
  • CSNK1α1 reduction prevents oncogene-induced cell transformation and tumor development in mice.

Conclusions:

  • Targeting CSNK1α1 represents a novel therapeutic strategy for multiple myeloma (MM), distinct from proteasome inhibition.
  • Combined inhibition of CSNK1α1 and bortezomib may enhance treatment efficacy in MM.
  • CSNK1α1 inhibition could potentially prevent the progression from monoclonal gammopathy of undetermined significance (MGUS) to MM.